Antengene Approved to Launch XPO1 Inhibitor for Multiple Myeloma

Shanghai Antengene announced that Xpovio® (selinexor), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE), was approved in China for relapsed or refractory multiple myeloma. It is  China 's first approved XPO1 inhibitor and Antengene's first approved product. The conditional approval is for second-line therapy in combination with dexamethasone. In 2018, Antengene in-licensed  China  rights to four novel oral drug candidates including Xpovio® from Boston 's Karyopharm in an $162 million agreement. More details.... Stock Symbol: (NSDQ: KPTI) Share this with colleagues: // //